COSENTYX Breakthrough: FDA Approves First IL-17A Inhibitor for Pediatric Hidradenitis Suppurativa, Offering Hope for Adolescents
The U.S. Food and Drug Administration (FDA) has granted a significant approval to Novartis's COSENTYX® (secukinumab), authorizing its use for...
